Kura Oncology, Inc. (KURA)
10.60
+0.08
(+0.76%)
USD |
NASDAQ |
Oct 09, 16:00
10.60
0.00 (0.00%)
After-Hours: 20:00
Kura Oncology Free Cash Flow : -117.43M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -117.43M |
| March 31, 2026 | -84.46M |
| December 31, 2025 | -70.70M |
| September 30, 2025 | 83.11M |
| June 30, 2025 | 122.86M |
| March 31, 2025 | 110.55M |
| December 31, 2024 | 133.84M |
| September 30, 2024 | -169.24M |
| June 30, 2024 | -154.84M |
| March 31, 2024 | -138.01M |
| December 31, 2023 | -124.99M |
| September 30, 2023 | -117.21M |
| June 30, 2023 | -109.55M |
| March 31, 2023 | -114.37M |
| December 31, 2022 | -110.69M |
| September 30, 2022 | -107.61M |
| June 30, 2022 | -111.54M |
| March 31, 2022 | -109.38M |
| December 31, 2021 | -105.70M |
| September 30, 2021 | -100.81M |
| June 30, 2021 | -93.13M |
| March 31, 2021 | -80.22M |
| Date | Value |
|---|---|
| December 31, 2020 | -72.00M |
| September 30, 2020 | -67.35M |
| June 30, 2020 | -61.86M |
| March 31, 2020 | -60.84M |
| December 31, 2019 | -54.76M |
| September 30, 2019 | -51.04M |
| June 30, 2019 | -51.89M |
| March 31, 2019 | -50.06M |
| December 31, 2018 | -48.66M |
| September 30, 2018 | -45.92M |
| June 30, 2018 | -39.15M |
| March 31, 2018 | -32.67M |
| December 31, 2017 | -28.44M |
| September 30, 2017 | -27.70M |
| June 30, 2017 | -26.94M |
| March 31, 2017 | -26.66M |
| December 31, 2016 | -25.35M |
| September 30, 2016 | -24.23M |
| June 30, 2016 | -23.21M |
| March 31, 2016 | -21.17M |
| December 31, 2015 | -17.99M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Inovio Pharmaceuticals, Inc. | -80.78M |
| Fortress Biotech, Inc. | 120.28M |
| Spero Therapeutics, Inc. | 19.58M |
| Gossamer Bio, Inc. | -164.59M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -62.55M |
| Cash from Investing (Quarterly) | 92.21M |
| Cash from Financing (Quarterly) | 1.499M |
| Free Cash Flow Per Share (Quarterly) | -0.7113 |
| Free Cash Flow to Equity (Quarterly) | -63.39M |
| Free Cash Flow to Firm (Quarterly) | -62.86M |
| Free Cash Flow Yield | -12.55% |